US-based firm Grail has started the STRIVE clinical trial to investigate and develop its blood tests for the early detection of cancer.
The multicentre, longitudinal, prospective, observational STRIVE study will enrol approximately 20,000 women who are due for their mammogram screening.
The study aims to train and validate a blood test for the detection of breast cancer.
STRIVE will also involve the development of a pan-cancer test to aid the early-stage detection of several cancers.
The Mayo Clinic and the Sutter Health system, Northern California, will enrol and collect baseline blood samples from the women.
Grail clinical development head Anne-Renee Hartman said: “In order to develop and validate a blood test for the early detection of breast cancer, we need the participation of up to 120,000 women.
"Grail's cutting-edge clinical technology enables us to enrol at scale and speed while collecting high-quality clinical outcomes data.
“We are extremely honoured to work with Sutter Health and Mayo Clinic on this endeavour and are thankful for the centres and participants who make this study possible.”
It is expected that the blood test will support the current breast cancer screening methods and will improve the likelihood of early and accurate identification.
Last December, Grail announced its first multicentre clinical study called Circulating Cell-free Genome Atlas (CCGA).
Through the firm's high-intensity sequencing approach, which sequences circulating nucleic acids at certain breadth and depth for early cancer detection optimisation, the CCGA study is designed to identify the prospects of cell-free nucleic acid profiles in cancer patients as well as in non-cancer subjects.
Image: New study to develop blood test for early cancer detection. Photo: courtesy of Praisaeng/ FreeDigitalPhotos.net.